A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide. by Weaver, A. et al.
British Journal of Cancer (1996) 74, 18218-1827
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
A study ofovarian cancer patients treated with dose-intensive chemotherapy
supported with peripheral blood progenitor cells mobilised by filgrastim and
cyclophosphamide
A Weaver', E Wrigley', A Watson', J Chang', CD Collins2, B Jenkins3, C Gill3, R Pettengell',
TM Dexter4, NG Testa4 and D Crowther'
'Cancer Research Campaign Department ofMedical Oncology, Christie Hospital, Manchester M20 4BX; 2Department of
Diagnostic Radiology, Christie Hospital, Manchester M20 4BX; 3Amgen, Cambridge CB4 4WD; 4Cancer Research Campaign
Department ofExperimental Haematology, Paterson Institute of Cancer Research, Manchester M20 4BX, UK.
Summary We have shown that large numbers of haemopoietic progenitor cells are mobilised into the blood
after filgrastim [granulocyte colony-stimulating factor (G-CSF)] alone and filgrastim following cyclopho-
sphamide chemotherapy in previously untreated patients with ovarian cancer. These cells may be used to
provide safe and effective haemopoietic rescue following dose-intensive chemotherapy. Using filgrastim alone
(10 pg kg'-), the apheresis harvest contained a median CFU-GM count of 45 x 104 kg-' and 2 x 106 kg-
CD34+ cells. Treatment with filgrastim (5 pg kg-1) following cyclophosphamide (3 gm-2) resulted in a
harvest containing 66 x 104 kg-' CFU-GM and 2.4x 106 kg-' CD34+ cells. There was no statistically
significant difference between these two mobilising regimens. We have also demonstrated that dose-intensive
carboplatin and cyclophosphamide chemotherapy can be delivered safely to patients with ovarian cancer when
supported by peripheral blood progenitor cells and filgrastim. Carboplatin (AUC 7.5) and cyclophosphamide
(900 mg m-2) given at 3 weekly intervals with progenitor cell and growth factor support was well tolerated in
terms of haematological and systemic side-effects. Double the dose intensity of chemotherapy was delivered
compared with our standard dose regimen when the treatment was given at 3 weekly intervals. Median dose
intensity could be further escalated to 2.33 compared with our standard regimen by decreasing the interval
between treatment cycles to 2 weeks. However, at this dose intensity less than a third ofpatients received their
planned treatment on time. All the delays were due to thrombocytopenia.
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Epithelial ovarian cancer is the fifth most common cause of
cancer death in women (Parkin et al., 1988). Despite
improvements in treatment resulting in increasing response
rates, relapse-free survival and overall survival since the
introduction of platinum chemotherapy and its derivatives,
such as carboplatin, a large proportion of women are still not
being cured of their disease.
One approach to improving these results is to consider the
use of drug regimens that deliver dose-intensive therapy. The
relationship between the dose intensity of chemotherapy and
survival in patients with ovarian carcinoma remains
controversial. A randomised study comparing a standard
dose combined chemotherapy regimen with treatment given
at half dose intensity but the same total dose was carried out
by our group. The patients receiving the lower dose intensity
had a significantly lower response rate and more patients
progressed during therapy. However, overall survival was not
significantly different (Murphy et al., 1993). Other prospec-
tive randomised trials have been reported examining standard
dose vs higher dose chemotherapy as first-line treatment for
epithelial ovarian cancer. In a randomised comparison by the
Gynaecology Oncology Group (GOG), 485 patients with
suboptimally debulked (,>1 cm) stage III or IV ovarian
cancer received either four cycles ofcisplatin 100 mg m-2 and
cyclophosphamide 1000 mg m-2 every 3 weeks or cisplatin
50 mg m-2 and cyclophosphamide 500 mg m-2 for eight
cycles. The received dose intensity ratio was 0.91:0.46, i.e.
2:1, while the total dose was the same for the two arms.
Response, median progression-free interval and survival rates
were similar but toxicity was greater in the dose-intensive arm
(McGuire et al., 1992). Similar results were reported by
Colombo et al. (1993) comparing cisplatin 50 mg m-2 weekly
for nine cycles with cisplatin 75 mg m-2 every 3 weeks for six
cycles. The dose intensity ratio was 2:1 and the total dose
remained constant. The Italian Group for Clinical Research
have reported a randomised trial of 101 patients comparing
cisplatin 100 mg m-2 weekly with a 5 week interval between
the third and fourth cycles with cisplatin 100 mg m-2 every 3
weeks for six cycles. The dose-intensity ratio was 1.6:1, and
again total dose was equivalent in the two arms. Overall
response and survival rates in the first 2 years were similar,
but survival diverged thereafter in favour of the dose
intensive arm, with the odds in the risk of dying at 8 years
of 0.10 (P=0.03) (Bella et al., 1994).
There are two reports of randomised trials in which higher
dose intensity and total dose have been associated with a
survival advantage (Kaye et al., 1992; Ngan et al., 1989).
Dose intensity and total dose may both contribute to
improved response and survival, but there remains consider-
able uncertainty regarding the possible benefit of dose-
intensive chemotherapy in patients with ovarian cancer and
further studies are warranted.
Over recent years haemopoietic growth factors, such as G-
CSF, have been used increasingly in an attempt to overcome
one of the major dose-limiting side-effects of high-dose
chemotherapy treatment, namely prolonged neutropenia.
Calvert et al. (1994) demonstrated that the dose of
carboplatin could be escalated up to a target area under
the curve (AUC) of 9 mg ml-' min-' every 2 weeks for four
cycles. However, thrombocytopenia became the dose-limiting
toxicity with >50% of cycles requiring platelet transfusions
at this AUC. Further dose escalation will not be possible
with G-CSF alone, since this agent has no effect on dose-
limiting thrombocytopenia.
Peripheral blood progenitor cells have, over recent years,
proved a convenient alternative to bone marrow transplanta-
tion following myeloablative chemotherapy, and their use
following high-dose chemotherapy leads to earlier recon
stitution of both white cell and platelet counts than with
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bone marrow infusions (Juttner et al., 1992). Priming patients
with haemopoietic growth factors, with or without
chemotherapy, enhances the yield of progenitor cells
(Socinski et al., 1988; Duhrsen et al., 1988; Gianni et al.,
1989) and the apheresis product obtained may be divided into
aliquots and reinfused following several cycles of dose-
intensive chemotherapy in order to support the patients'
neutrophil and platelet count. More recently, investigators
have studied the mobilisation of progenitor cells in healthy
donors by the administration of haemopoietic growth factors
alone. The apheresis products from these healthy donors have
been used to support patients following allogeneic transplan-
tation (Russell et al., 1993).
We have investigated the mobilisation of blood progenitor
cells using G-CSF alone in previously untreated ovarian
cancer patients, followed by the same patients being treated
with chemotherapy and G-CSF in order to compare the
mobilising effect of the two regimens. The study was also able
to determine whether an approximately 200% increase in
dose intensity over standard dose carboplatin and cyclopho-
sphamide could be safely administered with few side-effects
using G-CSF and blood progenitor cell support in patients
with ovarian carcinoma.
Patients, materials and methods
Patients
Previously untreated patients aged between 16 and 65 years
with histologically proven epithelial ovarian cancer, Interna-
tional Federation of Gynaecology and Obstetrics (FIGO)
stage Ic-IV were entered. All eligible patients were required
to have a normal full blood count. In addition, patients'
glomerular filtration rate (GFR) (measured using 51Cr-EDTA
clearance) had to be greater than 50 ml min-'. Fourteen
-patients were treated between April and September 1994. The
study was approved by South Manchester District Ethics
Committee and all patients gave written informed consent for
entry into the trial. A group of previously treated ovarian
cancer patients who received our standard dose chemother-
apy regimen was evaluated for comparison.
Treatment
All patients were initially treated with human recombinant
G-CSF (filgrastim) 10 ,ug kg-1 day-' subcutaneously (s.c.)
for 6 days before the first single apheresis (phase A). This
apheresis product was frozen and stored in liquid nitrogen for
use in patients whose blood count failed to recover following
chemotherapy. Following phase A the same patients were
treated with cyclophosphamide 3 g m-2and mesna 6 g m-2
given as a 4 h intravenous infusion on day 1, at least 48 h
after the first apheresis. Filgrastim 5 jg kg-' day-1 was
administered starting 24 h after chemotherapy until the
white blood count (WBC) was 4 x l091-1, when the
patients underwent a second single apheresis (phase B). The
product of this harvest was divided into four aliquots and
frozen in a controlled rate freezer in the vapour phase of
liquid nitrogen (Kryo 10; Planer Biomed Products, Ltd.
Middlesex, UK) and then transferred to liquid nitrogen and
stored at - 196°C.
The first seven patients were planned to receive treatment
at 3 weekly intervals, and the remaining seven patients were
planned to be treated at 2 weekly intervals with combined
chemotherapy (carboplatin and cyclophosphamide). Carbo-
platin dose was prescribed according to the Calvert formula
(Calvert et al., 1989) an AUC 7.5 mg ml - min-' using a
GFR measurement before each cycle of treatment, i.e.
carboplatin dose = 7.5 (EDTA clearance +25 mg).
Carboplatin was reconstituted in 1 1 of 5% dextrose and
infused over 1 h. Cyclophosphamide 900 mg m-2 was given
immediately after the carboplatin, infused over 1 h in 11 of
normal saline. Ondansetron and dexamethasone were
routinely given as antiemetics. Each cycle of combination
chemotherapy (phase C) was followed 24 h later by
reinfusion of one aliquot of the patient's own progenitor
cells collected during phase B. Filgrastim 5 jg kg-' day-'
was recommenced 24 h later and continued until absolute
neutrophil count (ANC) recovery (ANC >1 x 109 1` for 3
consecutive days or 10 x 109 1-1 for 1 day) was achieved.
Patients received four cycles of carboplatin/cyclophospha-
mide combination chemotherapy following the initial cycle of
single agent cyclophosphamide. Patients treated at 3 weekly
intervals were only treated when their WBC >3.0 x I109 (or
ANC > 1 x 109 1 ') and platelets >75 x I09 1-'. If the blood
count failed to recover at the time ofthe next planned cycle of
treatment the chemotherapy was delayed until recovery had
occurred. Treatments were always delivered at full dose and
never dose reduced.
Patients receiving chemotherapy at 2 weekly intervals were
only treated if their WBC ) 3.0x l091-' (or ANC
)I x I01 1-l) and platelets )50x 1091.
Peripheral blood progenitor cells were collected on a
Spectra cell separator (Cobe Laboratories, Lakewood, CO,
USA) using a continuous collection procedure until 2.5 times
the patient's blood volume had been processed. Platelet
transfusions were given to maintain a platelet count
) 20x l09 1- and red cell transfusions to maintain a
haemoglobin count of >8 g dl l.
Prestudy procedures
All patients were assessed by full physical examination,
including height, weight, vital signs, Karnofsky performance
status, full blood count, biochemistry (including liver
function tests), serum Ca 125, GFR (5'Cr-EDTA clearance)
and computerised tomography (CT) scan of abdomen and
pelvis.
Study procedures
Full blood counts, including manual different counts, were
performed as follows: phase A: days -7, -3, -2 and - 1;
phase B: days 1, 8, 10, 12, 14, 16, 18 and 20; phase C: twice
weekly.
Serum biochemistry and Ca 125 levels were measured on
day 1 of each cycle of chemotherapy. Progenitor cell
assessments (CFU-GM, BFU-E colony assays and CD34+
cell counts) were performed on peripheral blood samples on
the same days as the full blood counts described above and
also on the apheresis products from phases A and B.
Clonogenic progenitor cell assay
Ficoll-separated cells from the peripheral blood or apheresis
product were plated in modified Eagle's medium supplemen-
ted with penicillin and streptomycin and 0.66% (w/v) agarose
and overlayed on a gelled layer of modified Eagle's medium
supplemented with purified growth factors (rhSCF, rhIL-3,
rhIL-6 and rhGM-CSF at final concentrations of 50 ng ml-'
for CFU-GM assay, and rhSCF, rhIL-3, rhIL-6 and rhEPO
2 U ml-' for BFU-E assays) and 1% (w/v) agarose (Andrews
et al., 1992). Triplicate plates for each colony type, and cells
at final concentrations of 104 and 105 cells per plate were set
up, in addition to triplicate control plates substituting the
growth factors with phosphate-buffered saline. All growth
factors were supplied by Amgen, Thousand Oaks, CA, USA.
All plates were incubated at 37°C, in humidified 5% oxygen
and 5% carbon dioxide atmosphere. After 14 days, colonies
(>50 cells) were scored using a dissecting microscope.
CD34 analysis
An aliquot of 50 ,ul blood or apheresis product was labelled
with antiCD34, phycoerythrin (PE)- conjugated monoclonal
antibody (HPCA-2, Becton Dickinson, Mountain View, CA,
USA) and its isotype-matched control was always performed at
the same time. Cells were incubated at room temperature for15 min, the red cells then lysed (Ortho-mune Lysing reagent,
Ortho Diagnostic Systems, Raritan, NJ, USA), and washed in
phosphate-buffered saline. Cells were analysed by fluorescence-
activated cell sorting (FACScan, Becton Dickinson). For each
sample 50 000 cells were analysed (Siena et al., 1991).
Post-study procedures
All patients were subject to post-treatment evaluation
including physical examination, CT scan, full blood count,
serum biochemical profile and Ca 125 measurements.
Response assessment
Although the measurement of response rate was not a
primary objective of the study, tumour responses were
assessed using conventional criteria: complete remission
(CR), the disappearance of all known disease following
completion of treatment as assessed by clinical examination
and radiological investigation; partial remission (PR), >50%
decrease in the product of bidimensionally measured lesions
and the absence of new lesions; stable disease (SD), a <50%
decrease and <25% increase in the product of bidimension-
ally measured lesions; and progressive disease (PD), >25%
increase in the size of measured lesions, and/or the
appearance of new lesions.
Results
Fourteen patients were entered into the study, their median
age being 50 years (range 33-66 years). One patient was
withdrawn as a result of an allergic reaction to filgrastim,
therefore 13 patients have been analysed. Two of the 13
patients were not treated with the phase A regimen and have
therefore been excluded when comparing the apheresis
product from phases A and B. Two patients were FIGO
stage Ic, five patients stage II, four patients stage III and
three patients FIGO stage IV.
Apheresis product and peripheral blood
The results of peripheral blood progenitor cell mobilisation
using filgrastim (10 pg kg-') alone before chemotherapy
compared with cyclophosphamide followed by filgrastim
(5 ,g kg-') in the apheresis product are shown in Table I.
There was no significant difference in progenitor cell yields, in
terms of CFU-GM, BFU-E or CD34 cells, between the two
different mobilisation regimens. However, there was a
significant difference between the two regimens in terms of
mononuclear cell numbers mobilised. There were almost
three times as many mononuclear cells in the apheresis
product of the previously untreated patients following
filgrastim alone compared with yields using filgrastim
Table II Median peak
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following chemotherapy (Table I). Both filgrastim alone or
in combination with cyclophosphamide mobilised progenitor
cells extremely well, but there was no significant difference in
numbers of CFU-GM, BFU-E or CD34 cells mobilised per
ml of blood (Table II). The variation of progenitor and
mononuclear cell release into the peripheral blood with time
during phases A and B are shown in Figure la-c.
Response rates
CT scanning demonstrated complete remission in five
patients (35%) and partial remission in a further five
patients (35%), giving an overall response rate of 70%.
Measurable disease in two patients remained unchanged at
the end of treatment compared with their initial pretreat-
ment assessment. One patient had progressive disease
despite treatment and died within 4 months of completing
the study.
Delays ofchemotherapy
Our standard dose of combination chemotherapy for patients
with ovarian carcinoma consists of cyclophosphamide
Table I Progenitor cell yields from a single apheresis during phase
A and phase B
Phase B
Phase A Cyclophosphamide+
filgrastim flgrastim
lopg kg-' Sg kg-'
n=1I n=11 P-valuea
MNC x 108 kg-'
Median 8.5 2.9 P<0.01
Mean 8.4 3.2
s.d. 2.61 1.68
Range 3.5- 11.7 1.3-6.3
CFU-GM x 104 kg-'
Median 45 66 P=0.8
Mean 87 111
s.d. 98.5 129.2
Range 0-296 0-419
BFU-E x 104 kg-'
Median 71 98 P=0.8
Mean 119 168
s.d. 129.6 225.3
Range 0.1-382 0-767
CD34+ x 106 kg-'
Median 2.0 2.4 P=0.3
Mean 2.5 4.0
s.d. 1.46 4.53
Range 0.7-5.2 0.2- 16.1
aWilcoxon matched-pairs signed-rank sum test. MNC, mononuclear
cells.
values (ranges) of haemopoietic progenitor cells per millilitre of
peripheral blood
Phase B
Phase A Cyclophosphamide +
Filgrastim Filgrastim
Baseline 10 pg kg-' 5 pg kg-'
n=1I n=11 n=1I P-valuea
MNCx 105mI-' 14 145 27 P<0.01
(2-28) (35-364) (12- 169)
CFU-GM ml-' 53 5504 4915 P=0.9
(5- 562) (1850- 12857) (986- 147960)
BFU-E ml-' 108 4360 7776 P=0.6
(10-1043) (1850- 12857) (2242- 109069)
CD34+ x 103ml-' 2.7 66 75 P=0.6
(1.6-38) (17-548) (25-794)
aWilcoxon matched-pairs signed-rank sum test between phase A and phase B.Dose-intensive chemotherapy in ovarian cancer
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600 mg m-2 and carboplatin prescribed to an AUC
5 mg ml-' min-'. Treatment is given 3 weekly for a total
of six cycles.
The dose intensity for each drug was defined as the total
amount of drug delivered per unit time, expressed as mg m-2
week-' (Hryniuk, 1988) and relative dose intensity (Levin
and Hryniuk, 1987) as the amount of drug delivered per unit
time compared with the dose intensity of that drug in the
standard single-drug regimen, i.e.
Dose intensity in test regimen
Dose intensity in standard regimen
For drug combinations the average relative dose intensity
was calculated by dividing the sum of the relative dose
intensities in the test regimen by the number of drugs in the
regimen.
The six patients whose treatment was planned to be given
at 3 weekly intervals had an intended average relative dose
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Figure 1 Cells mobilised into the peripheral blood during phaseA and phaseB.
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4 nrsnt fnr%fintensity of 1.85 compared with our standard regimen, and
the patients treated at 2 weekly intervals had an intended
average relative dose intensity of 2.63. The first six patients
treated at 3 weekly intervals received all cycles of
chemotherapy as planned except for one patient who had a
delay of 1 week after the third cycle of treatment owing to
inadequate recovery of her platelet count. This resulted in the
six patients treated at 3 weekly intervals receiving 96% of
their planned chemotherapy on time and at full dose. The
median average relative dose intensity actually delivered was
1.85; five of the six patients (83%) received the planned dose
intensity.
We intended to treat seven patients at 2 weekly intervals
but of these only two patients completed their treatment as
planned. Two patients had a delay of 1 week, for one cycle
and each of the remaining three patients had three delays of 1
week for each of the last three cycles. All the delays were due
to inadequate recovery of the platelet count. The dose-
limiting toxicity of the 2 weekly regimen was thrombocyto-
penia. In this cohort of patients only 61% of chemotherapy
was delivered on time and at full dose. The median average
relative dose intensity actually delivered for this group was
2.33 compared with an intended average relative dose
intensity of 2.63; less than 30% of patients treated at 2
weekly intervals received their planned dose intensity (Table
III).
In order to put the results of the dose-intensive arms of
the study into context we have analysed a different group of
ten patients treated with standard dose carboplatin (AUC
5 mg ml-' min-') and cyclophosphamide (600 mg m-2) for
six cycles, during the same period as those patients receiving
dose-intensive treatment. Of these ten patients receiving
standard treatment only two completed all planned cycles
without any delay, i.e. 80% required at least one delay during
treatment. Out of a total of 60 cycles of treatment, 22 cycles
were delayed resulting in a median average relative dose
intensity of 0.91 and only 56% of the planned average dose
intensity delivered (Table III).
Neutropenic fever and haematological toxicity
Five of the 14 patients developed neutropenic fever (defined
as fever greater than 38°C and neutrophil count
< 1.0 x 109 1l) requiring hospital admission and intravenous
antibiotics using our standard policy. In four patients this
occurred following cyclophosphamide 3 g m-2 (phase B
mobilisation). A further patient developed neutropenic fever
during phase C treatment. There was no documented
evidence of sepsis and all febrile patients had negative blood
Dose-intensive chemotherapy in ovarian cancer
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cultures. The one patient developing neutropenic fever during
treatment phase C was being treated at 2 weekly intervals. All
patients recovered following intravenous antibiotics and no
patient required a delay in planned chemotherapy as a result
of these episodes. All patients experienced grade 4 toxicity
following cyclophosphamide 3 g m-2 during phase B with
nadir white blood counts < 1.0 x 109 1-I with corresponding
absolute neutrophil counts <0.5 x1091-'. Table IV shows
the median nadir white blood counts, absolute neutrophil and
platelet counts and their ranges during the four cycles of
carboplatin/cyclophosphamide (phase C) of treatment for the
two groups of patients. The median WBC, ANC and platelet
counts were generally higher for the patients treated at 3
weekly intervals compared with the equivalent cycle for the
patients treated at 2 weekly intervals. No patient at any stage
during the course of the study required the use of the reserve
harvest from phase A.
Non-haematological toxicities
One patient was withdrawn 3 days after entry owing to a skin
reaction associated with filgrastim administered at
Table IV Median nadir white blood counts (WBC), absolute
neutrophil counts (ANC) and platelet counts and their ranges
during phase C
Median nadir counts
WBCx 109 r' ANCx 109 FI Platelet x 109 F'
Cycle number (range) (range) (range)
Three weekly treatment
2 1.9 1.1 74
(0.5-4.5) (0.3-3.0) (12- 149)
3 2.2 0.9 70
(1.0-4.5) (0.4-3.4) (32-255)
4 2.0 1.4 64
(1.2-3.2) (0.4-2.2) (21 -121)
5 1.8 1.9 60
(0.7-4.2) (0.9-3.4) (14-130)
Two weekly treatment
2 1.3 0.7 142
(0.5-4.8) (0.1-3.7) (22-318)
3 0.8 0.4 43
(0.3-3.5) (0.1-0.7) (21 -173)
4 1.1 0.4 29
(0.6-5.9) (0.1 -3.7) (15- 163)
5 1.1 0.4 22
(0.6-6.3) (0.1-3.8) (9-80)
Table III Planned dose intensity and delays in chemotherapy
Median
average
Treatment Planned Percentage of cycles dose intensity Total number of
interval average delivered as delivered Patients Patients Cycles Cycles
Regimen (weeks) dose intensity planned (range) treated delayed delivered delayed
Cyclophosphamide 600mgM-2
Carboplatin AUC 5mg ml-1 min- 3 1 56 0.91 10 8 60 22
(six cycles) (0.78- 1)
Cyclophosphamide 3 g m-2 +
Cyclophosphamide 900 mg m-2 3 1.85 96 1.85 6 la 30 1
Carboplatin AUC (1.72-1.85)
7.5mg ml min
(four cycles)
Cyclophosphamide 3g m-2+
Cyclophosphamide 900mg m-2 2b 2.63 61 2.33 7 5a 35 11
Carboplatin AUC (2-2.63)
7.5mg ml' min
(four cycles)
aAll the delays in treatment were due to inadequate recovery ofplatelets. bThe treatment interval was 3 weeks after cyclophosphamide 3 g m-2
and 2 weeks for carboplatin/cyclophosphamide.Dose-intensive chemotherapy in ovarian cancer
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10 pg kg-'. This patient developed a disseminated maculo-
papular rash, with mild bone pain. All other patients
successfully completed the planned administration of
filgrastim, the only side-effect of note attributable to this
drug being bone pain during recovery from the nadir blood
count in phase A in one patient, and in three patients during
phase C. No patient, whether treated at 2 or 3 weekly
intervals, experienced more than grade 2 nausea or vomiting.
Only one patient had grade 1 and one patient grade 2
vomiting. All patients experienced grade 2 alopecia. Two
patients suffered grade 2 stomatitis and one patient grade 3.
No patient suffered sensory loss during the study. Symptoms
of constipation or diarrhoea occurred in nine patients but
were only of grade 1 severity.
Discussion
We have demonstrated that both filgrastim 10 pg kg-' given
alone and cyclophosphamide 3 g m-2 followed by filgrastim
5 pg kg-1 result in effective mobilisation of peripheral blood
progenitor cells in previously untreated patients with
epithelial ovarian cancer. Although the median number of
progenitor cells mobilised following cyclophosphamide
3 g m-2 and filgrastim 5 pg kg-' was greater than that
following mobilisation with filgrastim 10 pg kg-' alone, this
difference was not statistically significant. There was
considerable individual patient variation in the number of
progenitor cells mobilised. Studies investigating the effects of
filgrastim dose on mobilisation of progenitor cells have
demonstrated that there is a dose-response relationship, with
10 pug kg-' of filgrastim mobilising more cells than
7.5 pug kg-', which in turn mobilises more than 5 pg kg-'
(Stronceck et al., 1994). In our study patients received
filgrastim 10 pg kg-' alone during phase A but only
5 pg kg-' when used following cyclophosphamide (phase
B), hence a possible explanation for the lack of significant
difference between the two mobilisation regimens may be due
to the difference in filgrastim dose administered. Our results
are also very similar to those reported by Feremans et al.
(1994) regarding the numbers ofprogenitor cells mobilised by
G-CSF (10 pg kg-') alone compared with mobilisation
produced using cyclophosphamide 4 g m-2 and G-CSF
5 pg kg-' in the same patients being treated for myeloma.
As we have not demonstrated a significant difference in
progenitor cell mobilisation between the two regimens
studied, it would be reasonable to use filgrastim alone
(10 pg kg-') to mobilise normal healthy donors, thereby
avoiding toxic chemotherapy in these patients. However,
when mobilising patients with cancer it may be an advantage
to incorporate chemotherapy as part of the mobilisation
regimen, not only to enhance mobilisation of progenitor cells
but also to provide effective treatment against the cancer and
reduce the potential for reinfusion ofviable malignant cells in
the apheresis product.
Patients treated with the dose-intensive regimen at 3
weekly intervals tolerated the treatment extremely well and
five of the six patients (83%) received the planned dose
intensity of 1.85. Therefore, this 3 weekly intensive
chemotherapy regimen of cyclophosphamide and carboplatin
with filgrastim and progenitor cell support can be safely
administered with very little haematological or systemic
toxicity, while being able to deliver double the dose intensity
(1.85:0.91) achieved in patients receiving our standard
therapy.
Patients treated with the 2 weekly dose-intensive regimen
suffered more delays compared with the 3 weekly dose-
intensive regimen. Only two of the seven patients (29%)
received their planned treatment on time and at full dose. Of
the 35 cycles of chemotherapy delivered to this group of
patients, 11 had to be delayed, all due to thrombocytopenia.
We have reached the maximum tolerated dose by adminis-
tering this dose-intensive regimen at 2 weekly intervals, with
only 61% of planned cycles being delivered on time. Unless
the platelet count can be supported further during the
administration of such dose-intensive regimens it will not be
possible to escalate the dose beyond 2 weekly therapy using
this regimen. Although thrombocytopenia was dose limiting
in the 2 weekly regimen, subjective toxicity and other
haematological toxicities were no different from the 3 weekly
therapy. The dose-intensive regimens described in the paper
were equally as well tolerated as the standard regimen.
However, increasing the dose intensity further would be less
tolerable.
The overall response rate for the study patients was 70%,
with 35% achieving complete remission, although care should
be taken not to overinterpret these figures in view of the
small numbers of patients involved.
Our study has demonstrated that 3 weekly dose-intensive
chemotherapy can be administered safely with very low, and
hence acceptable, levels of toxicity using peripheral blood
progenitor cells and filgrastim support. However, escalating
the dose intensity using a 2 weekly schedule resulted in less
than a third of patients receiving their treatment as planned
owing to thrombocytopenia. The 3 weekly dose-intensive
schedule with double the dose intensity of our standard
chemotherapy provides a regimen for evaluating the role of
dose-intensive chemotherapy in patients with ovarian
carcinoma within the context of a randomised trial with
similar adverse effects in both treatment arms.
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